Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

(2018) Liqin Wang et al.   CELL

A genetic interaction analysis identifies cancer drivers that modify EGFR dependency

(2017) Sida Liao et al.   GENES & DEVELOPMENT

Ribosomopathies: There’s strength in numbers

(2017) Eric W. Mills et al.   SCIENCE

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

(2016) D. Oddo et al.   CANCER RESEARCH

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

(2016) Che-Hung Shen et al.   NATURE MEDICINE

High-resolution interrogation of functional elements in the noncoding genome

(2016) N. E. Sanjana et al.   SCIENCE

The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)

(2016) Andrew M. Kidger et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Epigenetic Determinants of Cancer

(2016) Stephen B. Baylin et al.   Cold Spring Harbor Perspectives in Biology

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

(2015) Douglas B. Johnson et al.   EUROPEAN JOURNAL OF CANCER

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

(2014) Georgina V. Long et al.   Nature Communications

Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer

(2013) J. M. Balko et al.   CANCER RESEARCH

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance, epigenetics and the cancer ecosystem

(2011) Stephen B Baylin   NATURE MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ribosomopathies: human disorders of ribosome dysfunction

(2010) A. Narla et al.   BLOOD

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA